Editas Medicine (EDIT) to Release Quarterly Earnings on Monday

Key Points

• Editas Medicine will report Q1 2026 results before the market opens on May 11, 2026; analysts expect EPS of ($0.30) and revenue of about $5.88 million, with the earnings call at 12:30 PM ET.
• In the prior quarter the company beat estimates (EPS of $0.06 loss vs. consensus $0.27 loss; revenue $24.74M vs. $8.77M), but it remains unprofitable with negative margins and analysts projecting about -$1 EPS for the current and next fiscal year.
• Institutional investors own roughly 71.9% of the stock after sizable buys by Renaissance, UBS and others, while analyst sentiment is mixed but the consensus is a "Moderate Buy" with a target price of $5.30; the stock trades near $2.99 with a market cap of about $292M.

Editas Medicine (NASDAQ:EDIT - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Editas Medicine to post earnings of ($0.30) per share and revenue of $5.8840 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 12:30 PM ET.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.21. The business had revenue of $24.74 million during the quarter, compared to the consensus estimate of $8.77 million. Editas Medicine had a negative return on equity of 389.73% and a negative net margin of 395.02%. On average, analysts expect Editas Medicine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Editas Medicine Price Performance

Shares of EDIT stock traded up $0.09 during trading hours on Monday, reaching $2.99. 370,333 shares of the company's stock were exchanged, compared to its average volume of 1,692,604. The company has a market cap of $292.26 million, a P/E ratio of -1.58 and a beta of 2.14. The company's 50 day moving average is $2.61 and its two-hundred day moving average is $2.49. Editas Medicine has a 1 year low of $1.29 and a 1 year high of $4.54.

Institutional Investors Weigh In On Editas Medicine

A number of large investors have recently bought and sold shares of EDIT. Renaissance Technologies LLC boosted its holdings in shares of Editas Medicine by 138.0% during the fourth quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company's stock worth $6,232,000 after purchasing an additional 1,762,378 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Editas Medicine by 122.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company's stock worth $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Editas Medicine by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company's stock worth $4,685,000 after purchasing an additional 244,574 shares during the last quarter. State Street Corp boosted its holdings in shares of Editas Medicine by 2.6% during the fourth quarter. State Street Corp now owns 1,974,931 shares of the company's stock worth $4,049,000 after purchasing an additional 49,887 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Editas Medicine by 63.3% during the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company's stock worth $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Institutional investors and hedge funds own 71.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Chardan Capital reissued a "buy" rating and set a $3.50 target price on shares of Editas Medicine in a research note on Monday, March 9th. Robert W. Baird set a $6.00 target price on Editas Medicine in a report on Monday, March 9th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Editas Medicine in a report on Monday, April 20th. TD Cowen reiterated a "buy" rating on shares of Editas Medicine in a report on Monday, March 9th. Finally, Wall Street Zen upgraded Editas Medicine from a "sell" rating to a "hold" rating in a report on Saturday. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.30.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.